Matches in Wikidata for { <http://www.wikidata.org/entity/Q105786979> ?p ?o ?g. }
Showing items 1 to 39 of
39
with 100 items per page.
- Q105786979 description "clinical trial" @default.
- Q105786979 description "ensayo clínico" @default.
- Q105786979 description "ensayu clínicu" @default.
- Q105786979 description "klinisch onderzoek" @default.
- Q105786979 description "клінічне випробування" @default.
- Q105786979 description "临床试验" @default.
- Q105786979 name "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma" @default.
- Q105786979 name "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma" @default.
- Q105786979 type Item @default.
- Q105786979 label "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma" @default.
- Q105786979 label "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma" @default.
- Q105786979 prefLabel "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma" @default.
- Q105786979 prefLabel "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma" @default.
- Q105786979 P1050 Q105786979-742B9ABF-5F6F-449F-83DA-B85BF3EEA142 @default.
- Q105786979 P1050 Q105786979-BF2B3C9E-FD2F-438B-8242-2068F0D9A397 @default.
- Q105786979 P1132 Q105786979-5A13454A-3459-401E-A7EC-94A7F70CB92E @default.
- Q105786979 P1476 Q105786979-A7FA94C1-A3AB-46C5-86E7-6F5094335F5C @default.
- Q105786979 P3098 Q105786979-0410D746-FAEE-4BC3-A081-DA843B39964E @default.
- Q105786979 P31 Q105786979-B8B17BFA-6EDA-43B2-B5D0-3DA1DBEC8E4E @default.
- Q105786979 P4135 Q105786979-21C7F457-0C2B-4E60-9E4A-61A83E004B56 @default.
- Q105786979 P580 Q105786979-8BE3A17A-B60F-44DA-809D-609145865C6C @default.
- Q105786979 P582 Q105786979-F740275B-4ADA-40DD-A56D-15470FEE9C51 @default.
- Q105786979 P6099 Q105786979-7DCCA95B-E9AD-4617-B3C8-E9ED33989663 @default.
- Q105786979 P8005 Q105786979-E991D129-6AA7-4B5A-B43C-E751CD887C65 @default.
- Q105786979 P8363 Q105786979-D73C967C-3CDC-4D13-A3A8-74D78BA08D1B @default.
- Q105786979 P859 Q105786979-03A3DADF-0203-45C4-916A-00E585F6768E @default.
- Q105786979 P1050 Q549534 @default.
- Q105786979 P1050 Q938205 @default.
- Q105786979 P1132 "+82" @default.
- Q105786979 P1476 "Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed Osteosarcoma" @default.
- Q105786979 P3098 "NCT04751383" @default.
- Q105786979 P31 Q30612 @default.
- Q105786979 P4135 "+35" @default.
- Q105786979 P580 "2021-04-16T00:00:00Z" @default.
- Q105786979 P582 "2024-01-31T00:00:00Z" @default.
- Q105786979 P6099 Q5452194 @default.
- Q105786979 P8005 Q76649614 @default.
- Q105786979 P8363 Q78089383 @default.
- Q105786979 P859 Q664846 @default.